Tüdőrák: vizsgálatok itt: Ausztria
58 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 12.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Where
- Feldkirch, Innsbruck, Krems An Der Donau, Vienna
- Életkor
- 18 év and over
- People
- 1160 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06692738 · EU 2024-514281-39-00 - 1. fázisTaking peopleBeamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
- Where
- Linz
- Életkor
- 18 év and over
- People
- 554 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT04886804 · EU 2024-511246-39-00 - 3. fázisTaking peoplePhase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Where
- Feldkirch, Innsbruck, Krems An Der Donau, Linz, Vienna, Wels
- Életkor
- 18 év and over
- People
- 675 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06357533 · EU 2023-505077-32-00 - 3. fázisTaking peopleA Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
- Where
- Vienna
- Életkor
- 18 év and over
- People
- 390 worldwide
- Run by
- ETOP IBCSG Partners Foundation
See details and how to joinNCT06931717 · EU 2024-519901-36-00 - 3. fázisTaking peopleA Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Where
- Graz, Linz, Vienna, Wels
- Életkor
- 18 év and over
- People
- 630 worldwide
- Run by
- Mirati Therapeutics Inc.
See details and how to joinNCT06875310 · EU 2024-515698-85-00 - 2/3. fázisTaking peopleA Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Where
- Feldkirch, Linz, Vienna
- Életkor
- 18 év and over
- People
- 590 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07063745 · EU 2025-521511-40-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- Where
- Feldkirch, Linz, St. Poelten
- Életkor
- 18 év and over
- People
- 750 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07361510 · EU 2025-523586-18-00 - 3. fázisTaking peopleA Study to Test How Well ZL-1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell Lung Cancer
- Where
- Salzburg, Vienna
- Életkor
- 18 év and over
- People
- 263 worldwide
- Run by
- Zai Lab (US) LLC
See details and how to join2025-522818-23-00 - 1/2. fázisTaking peopleStudy of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
- Where
- St. Poelten, Vienna
- Életkor
- 18 év and over
- People
- 616 worldwide
- Run by
- Revolution Medicines, Inc.
See details and how to joinNCT06162221 · EU 2025-521147-21-00 - No phaseTaking peoplePRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study)
- Where
- Graz
- Életkor
- 18 év and over
- People
- 600 worldwide
- Run by
- European Organisation for Research and Treatment of Cancer - EORTC
See details and how to joinNCT04790253 - 3. fázisTaking peopleA Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
- Where
- Salzburg, Vienna
- Életkor
- 18 év and over
- People
- 480 worldwide
- Run by
- Zai Lab (Shanghai) Co., Ltd.
See details and how to joinNCT07218146 - 2/3. fázisTaking peopleA Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- Where
- Vienna
- Életkor
- 18 év and over
- People
- 490 worldwide
- Run by
- AbbVie
See details and how to joinNCT07155187 · EU 2025-521124-29-00 - 1. fázisTaking peopleStudy of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Where
- Graz, Vienna
- Életkor
- 18 év and over
- People
- 1394 worldwide
- Run by
- Exelixis
See details and how to joinNCT05176483 · EU 2023-510061-10-00 - 3. fázisTaking peopleNeladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- Where
- Innsbruck, Vienna
- Életkor
- 18 év and over
- People
- 450 worldwide
- Run by
- Nuvalent Inc.
See details and how to joinNCT06765109 · EU 2024-517553-26-00 - 3. fázisTaking peopleThis is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Where
- Graz, Linz, Vienna
- Életkor
- 18 év and over
- People
- 714 worldwide
- Run by
- Pfizer
See details and how to joinNCT06758401 · EU 2024-517968-36-00 - 3. fázisTaking peopleA Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
- Where
- Innsbruck, Krems An Der Donau, Linz
- Életkor
- 18 év and over
- People
- 531 worldwide
- Run by
- AbbVie
See details and how to joinNCT07365241 · EU 2025-523819-11-00 - 2. fázisTaking peopleRepotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis
- Where
- Graz, Vienna
- Életkor
- 18 év and over
- People
- 20 worldwide
- Run by
- MedSIR
See details and how to joinNCT06315010 · EU 2023-508112-35-00 - 3. fázisTaking peopleStudy Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLLphi-312)
- Where
- Graz, Krems An Der Donau
- Életkor
- 18 év and over
- People
- 156 worldwide
- Run by
- Amgen Inc.
See details and how to join2024-520050-38-00 - 3. fázisTaking peopleA Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
- Where
- Feldkirch, Krems An Der Donau, Linz, Vienna
- Életkor
- 18 év and over
- People
- 540 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06203210 · EU 2023-509628-16-00 - No phaseTaking peopleEXERCISE AND THE IMMUNE RESPONSE IN LUNG CANCER
- Where
- Graz
- Életkor
- 18 év to 75 év
- People
- 50
- Run by
- Medical University of Graz
See details and how to joinNCT07267000 - 2. fázisNot yet taking people in AusztriaPhase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets
- Where
- Linz, Vienna
- Életkor
- 18 év and over
- People
- 158 worldwide
- Run by
- European Organisation for Research and Treatment of Cancer - EORTC
See details and how to joinNCT07234877 · EU 2025-522985-60-00 - No phaseTaking peopleConfocal Laser Endomicroscopy VERification
- Where
- Vienna
- Életkor
- 18 év and over
- People
- 208 worldwide
- Run by
- Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)
See details and how to joinNCT06079970 - No phaseTaking peopleReal-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab
- Where
- Sankt Pölten
- Életkor
- 18 év and over
- People
- 240 worldwide
- Run by
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
See details and how to joinNCT07510724 - No phaseTaking peoplePartial Tumor Irradiation and Immunotherapy for Unresectable Lung Cancer
- Where
- Krems
- Életkor
- 18 év and over
- People
- 10
- Run by
- Karl Landsteiner University of Health Sciences
See details and how to joinNCT07423169 - No phaseTaking peopleDiscrimination of N2a and N2b by EBUS-TBNA: is a Change of the Needle Necessary?
- Where
- Vienna
- Életkor
- 18 év and over
- People
- 30
- Run by
- University of Vienna
See details and how to joinNCT07418450